Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Varespladib Followed by Oral Varespladib in Addition to Standard of Care in Subjects Bitten by Venomous Snakes

NCT05717062 is registered in ClinicalTrials.gov with Ophirex, Inc. as lead sponsor.

NCT NCT05717062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Varespladib Followed by Oral Varespladib in Addition to Standard of Care in Subjects Bitten by Venomous Snakes
Lead sponsor
Ophirex, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 30, 2023
Completion date
February 24, 2025
Enrollment
140 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

envenoming, snake, snakebite